Table 1.
Preoperative clinical and postoperative pathologic characteristics of the entire set of participants
| Variable | All patients (n = 1,918) |
|---|---|
| Demographic and laboratory parameter | |
| Male gender | 1,496 (78.0) |
| Age, years | 56.0±9.8 |
| Etiology of liver disease | |
| HBV infection | 1,623 (84.6) |
| HCV infection | 104 (5.4) |
| Others | 191 (10.0) |
| Serum AST, IU/L | 49±38 |
| Serum ALT, IU/L | 42±37 |
| Platelet count, ×103/mm3 | 163±57 |
| Prothrombin time, INR | 1.04±0.07 |
| Serum creatinine, mg/dL | 0.9±0.5 |
| Serum albumin, g/dL | 4.0±0.4 |
| Serum bilirubin, mg/dL | 0.8±0.3 |
| Serum AFP level, ng/mL | 2,835.6±23,912.0 |
| Serum AFP ≥200 ng/mL | 533 (27.8) |
| Pathologic parameter | |
| Maximal tumor diameter, cm | 4.0±2.8 |
| <3 | 827 (43.1) |
| 3–5 | 713 (37.2) |
| >5 | 378 (19.7) |
| Tumor multiplicity | 174 (9.1) |
| Microscopic vascular invasion | 363 (18.9) |
| Capsular invasion | 138 (7.1) |
| Histological differentiation* | |
| Well differentiated | 1,335 (69.6) |
| Moderately differentiated | 560 (29.2) |
| Poorly differentiated | 23 (1.2) |
| Stage of liver fibrosis† | |
| F0 | 134 (7.0) |
| F1 | 329 (17.2) |
| F2 | 344 (17.9) |
| F3 | 55 (2.9) |
| F4 | 1,056 (55.0) |
Values are expressed as mean±SD, or frequency (%). HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; AFP, alpha-fetoprotein; SD, standard deviation.
*
Histological differentiation was based on 2019 WHO classification.
†
Liver fibrosis was staged according to the METAVIR scoring system: F0, absence of fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with rare septa; F3, numerous septa without cirrhosis; F4, cirrhosis.